GERN geron.com: יחס שווי פעילות לרווח לפני ריבית, מסים ופחת

FDA approval of Rytelo has strengthened the patent moat of Geron Corporation (GERN) through unique telomerase inhibitors. The EV/EBITDA multiple in a historical context on the GURU.Markets chart demonstrates market trends, where the 0.00 mark serves as a key metric. Monopoly pricing power within the myelodysplastic syndromes therapy niche and the launch of an innovative drug provide the company with high margins and a stable inflow of free cash flow.

For Geron Corporation, which is launching a drug in the hematology segment, it is critical to evaluate business value through the lens of EBITDA. This metric compares the total enterprise value with its ability to generate cash flow, neutralizing the impact of debt load and tax regimes. Analyzing the EV/EBITDA ratio alongside the capital structure allows for the determination of the issuer's fair value during its expansion in the US market.